Dietary Riboflavin (Vitamin B-2) and Cornea Cross-Linking

Launched by UNIVERSITY OF MISSOURI-COLUMBIA · Mar 23, 2017

Keywords

ClinConnect Summary

This clinical trial is exploring the effects of dietary riboflavin, also known as vitamin B-2, combined with natural sunlight exposure in treating conditions like keratoconus and corneal ectasia. These conditions involve the thinning and irregular shape of the cornea, which can lead to distorted vision. The study aims to see if this simple approach can stabilize the cornea's shape as effectively as more expensive treatments currently available, like the collagen cross-linking procedure.

To participate in the trial, individuals must be diagnosed with keratoconus or post-refractive cornea ectasia, with a specific level of astigmatism. Those with known sensitivities to riboflavin or sunlight, or certain medications that increase sunlight sensitivity, should talk to their doctor before joining. Participants can expect to take riboflavin supplements and spend some time in natural sunlight each day, with ongoing monitoring of their vision and corneal health. If successful, this study could lead to more affordable treatment options for patients needing corneal stabilization.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients identified as having keratoconus or post refractive cornea ectasia with astigmatism of 1.5 Diopters or greater.
• Exclusion Criteria:
• • Known sensitivity to riboflavin, sunlight.
• • patients on medications with side effects of increased sunlight sensitivity should discuss participation with their prescribing provider prior to participation